inflammatory bowel disease
Conditions
Interventions
Study Group:None
Control Group:None
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 57 Years
Inclusion criteria
Inclusion criteria: Study Group: 1. Age of 18-60 years old, male or female; 2. Patients diagnosed with ulcerative colitis or Crohn's disease by clinical manifestations and histological examination; 3. Crohn's disease activity was assessed by modified Mayo score and Crohn's disease activity index (CDAI) at diagnosis; 4. No history of gastrointestinal tumors, anorectal or colon surgeries, or any pelvic/abdominal surgeries; no symptoms indicative of tumors. 5. No severe diseases of the heart, lungs, liver, kidneys, blood, endocrine system, or connective tissue diseases/rheumatic diseases; no peripheral or autonomic nervous system diseases. 6. No history of drug use or substance abuse. 7. No use of gastrointestinal motility drugs or probiotics in the past week. 8. Agrees to participate in the study and signs the informed consent form. Control Group: 1. Age of 18-60 years old, male or female; 2. Gender and age matched with the study group; 3. No history of gastrointestinal tumors, anorectal or colon surgeries, or any pelvic/abdominal surgeries; no symptoms indicative of tumors. 4. No severe diseases of the heart, lungs, liver, kidneys, blood, endocrine system, or connective tissue diseases/rheumatic diseases; no peripheral or autonomic nervous system diseases. 5. No history of drug use or substance abuse. 6. No use of gastrointestinal motility drugs or probiotics in the past week. 7. Agrees to participate in the study and signs the informed consent form.
Exclusion criteria
Exclusion criteria: Study Group: 1. Age under 18 or over 60 years old; 2. Patients who do not meet the diagnostic criteria for ulcerative colitis or Crohn's disease; 3. Patients in the remission phase of the disease; 4. History of gastrointestinal tumors, anorectal or colon surgeries, or any pelvic/abdominal surgeries; patients with symptoms indicative of tumors; 5. Concurrent severe diseases of the heart, lungs, liver, kidneys, blood, endocrine system, or connective tissue diseases/rheumatic diseases, or peripheral or autonomic nervous system diseases; 6. History of drug use or substance abuse; 7. Use of gastrointestinal motility drugs or probiotics within the past week; 8. Refusal to participate in the study and sign the informed consent form.; Control Group: 1. Age under 18 or over 60 years old; 2. Gender and age do not match the study group; 3. Presence of gastrointestinal tumors, colonic adenomatous polyps, or juvenile polyps; patients with symptoms indicative of tumors; 4. Presence of severe diseases of the heart, lungs, liver, kidneys, blood, endocrine system, or connective tissue diseases/rheumatic diseases, or peripheral or autonomic nervous system diseases; 5. History of drug use or substance abuse; 6. Use of gastrointestinal motility drugs or probiotics within the past week; 7. Refusal to participate in the study and sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gastric motility index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Gastric emptying rate;Frequency of antral contraction;Amplitude of antral contraction;Frequency of small bowel contraction;Amplitude of contraction of small intestine;Small intestinal motility index; | — |
Countries
China
Contacts
Public ContactYan Chi
Peking University First Hospital
Outcome results
None listed